… guide RNA can mimic the effect of hyperactive mutants and advance the approach of recruiting endogenous ADARs for site-directed RNA editing reported in Journal of … (E488 in human ADAR2), which flips the adenosine into the ADAR active site for deamination. Mutating this residue to …
… chemical modifications of EONs and the side-chains of the ADAR2 deaminase domain. Our data have been successfully … structure-based computational tools to other domains of ADARs and combine in silico screening with data from …
… specific RNA for A-to-I editing by recruiting endogenous Adenosine Deaminase Acting on RNA (ADAR). The therapeutic possibilities of this editing platform …
Progress on Development of RNA Base Editing Technologies for Precision Medicines, including Axiomer® platform presented at TIDES EU by Gerard Platenburg - ProQR Therapeutics
… and Director of the NIH-funded UC Davis Chemical Biology Graduate Program. For over 25 years, work in the Beal laboratory has advanced understanding of the structures and mechanism of action for the ADAR enzymes responsible for adenosine to inosine RNA editing …
This presentation highlights the therapeutic possibilities of Axiomer platform that are not limited to disease causing mutations and can potentially address high unmet medical needs by editing wild-type RNA to engineer proteins or modify their function as well as creating de novo mutations.
… specific RNA for A-to-I editing by recruiting endogenous Adenosine Deaminase Acting on RNA (ADAR). Through now further developed design principles there …
… recruit and direct the cells own editing machinery called ADAR (adenosine deaminase acting on RNA). EONs will guide the ADARs to perform a single nucleotide change at the RNA level …
